Cartherics wins SITC 2026 oral slot for ovarian cancer cell therapy
Cartherics will present new data on CTH-401, its off-the-shelf ovarian cancer cell therapy, at the Society for Immunotherapy of Cancer 2026 Annual Meeting in Phoenix. The company says the program is nearing a first-in-human trial in early 2027, pending regulatory approval.
Why it matters: - Ovarian cancer causes more than 200,000 deaths worldwide each year. - Most patients are diagnosed at an advanced stage. - Fewer than 30% of patients survive five years. - CTH-401 is Cartherics’ lead product candidate for ovarian cancer and part of a broader effort to build off-the-shelf immune cell therapies for high-impact women’s diseases.
What happened: - Cartherics will present an update on CTH-401 at the Society for Immunotherapy of Cancer 2026 Annual Meeting in Phoenix, Arizona. - Deputy Chief Scientific Officer Dr. Keefe Chan will deliver an oral presentation and show a poster. - The oral presentation is scheduled for Oral Abstract Session 2 on Friday, Nov. 6, from 3:58 to 4:13 p.m. Mountain Time. - The poster number is 161. - The presentation title is “CTH-401: Allogeneic iPSC-derived CAR-NK cells for the treatment of ovarian cancer.”
The details: - CTH-401 is an off-the-shelf immune cell therapy made from induced pluripotent stem cells. - The therapy is engineered to target TAG-72, a protein found on ovarian and other adenocarcinomas with negligible expression on normal adult tissues. - CTH-401 carries two gene deletions, DGKα and DGKζ, which remove an internal brake that normally dampens natural killer cell function after activation. - Cartherics manufactures CTH-401 in its own clinical manufacturing facility in Melbourne. - The product is made in advance from a master cell bank. - The design is intended to support scale manufacturing and off-the-shelf availability, rather than custom production for each patient. - Key findings to be presented include consistent manufacturing from a fully characterized, GMP-compliant master cell bank. - Laboratory studies showed CTH-401 killed TAG-72-positive cancer cells. - The gene deletions significantly improved the cells’ resistance to tumor immunosuppression. - Preclinical work showed significant tumor control in an ovarian cancer model. - GLP toxicology studies showed an acceptable safety profile at dose equivalents well above the intended clinical range. - IND-enabling studies are complete. - Cartherics is targeting a first-in-human ovarian cancer trial in early 2027, pending regulatory approval. - TAG-72 is also expressed in colorectal, gastric and other adenocarcinomas. - Cartherics’ iPSC platform is also designed to support additional products, including programs in endometriosis. - The company says its Melbourne facility brings discovery, process development and clinical manufacturing together under one roof, giving direct control over quality, cost and timelines as CTH-401 moves toward the clinic. - Read the abstract published in the Journal for ImmunoTherapy of Cancer.
Between the lines: - An oral presentation at SITC gives the program higher visibility among cancer immunotherapy researchers and potential partners. - The combination of scalable manufacturing, preclinical tumor control and acceptable toxicology data suggests Cartherics is pushing CTH-401 toward clinical testing with fewer obvious technical hurdles. - The broader TAG-72 target profile could open the door to other solid tumors if the ovarian cancer program advances.
What's next: - Cartherics plans to advance CTH-401 toward a first-in-human trial in ovarian cancer in early 2027 if regulators approve. - The company is also positioning its platform for future programs beyond ovarian cancer, including endometriosis and additional solid tumors.
The bottom line: - Cartherics is using SITC 2026 to showcase an off-the-shelf cell therapy that has manufacturing, safety and preclinical efficacy data lined up ahead of a planned 2027 clinical trial.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Educators Post Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.